For example, data from the phase II PRODIGE 35-PANOPTIMOX trial showed comparable overall survival (OS) among previously untreated patients with advanced disease who received 6 months of FOLFIRINOX versus 4 months of FOLFIRINOX followed by 5-fluorouracil/leucovorin (LV5FU2). Read more . . .
Chemotherapy has been a mainstay in advanced pancreatic cancer, but it can be challenging for patients to tolerate, according to Shubham Pant, MD, who added that de-escalated maintenance approaches could be one way to help patients preserve their quantity and quality of life.